Arginine vasopressin (AVP) and oxytocin (OXT) are synthesized in the magnocellular neurosecretory cells (MNCs) of the hypothalamic paraventricular (PVN) and supraoptic nuclei (SON) that terminate their axons in the posterior pituitary (PP). Recently, we generated transgenic rats that express AVP-enhanced green fluorescent protein (eGFP) fusion gene and OXT-monomeric red fluorescent protein 1 (mRFP1) fusion gene in order to visualize AVP or OXT in the hypothalamo-neurohypophysial system (HNS). Colchicine is known to block axonal transport, resulting in peptide accumulation in the cell body. We investigated the effects of intracerebroventricular (icv) administration of colchicine on the expression of AVP-eGFP fusion or OXT-mRFP1 fusion gene products. Icv administration of colchicine caused a marked increase of AVP-eGFP and OXT-mRFP1 fluorescence in the hypothalamic MNCs, and a decrease in the PP in comparison with control rats. The expected changes of AVPeGFP and OXT-mRFP1 fluorescence in the HNS after icv administration of colchicine indicate that AVP-eGFP and OXT-mRFP1 fusion protein may be transported by axonal flow and secreted from the PP into the systemic circulation. These transgenic rats are new tools to study the physiological role of AVP and OXT in the HNS.
Introduction
Arginine vasopressin (AVP) and oxytocin (OXT) are nine amino acid neuropeptides, and the structure of AVP differs from that of OXT by only 2 amino acids. Both peptides are synthesized primarily in magnocellular neurosecretory cells (MNCs) in the hypothalamic supraoptic (SON) and the paraventricular nuclei (PVN). These cells project their axon terminals into the posterior pituitary (PP), where the peptides are released into the systemic circulation [5] . AVP plays a role in water homeostasis and cardiovascular regulation, and also controls osmolality and blood pressure. OXT is well known for its roles in reproduction, especially during and after childbirth. OXT is also involved in several physiological functions, such as antinociception, anxiety, feeding, social recognition and stress responses [12, 13, 50, 73, 89, 104] .
We have recently reported the generation and characterization of rats which faithfully express an AVP-enhanced green fluorescent protein (eGFP) fusion transgene [25, 37, 53, 66, 82, 90, 99, 102] . We also succeeded in generating transgenic rats bearing an OXT-monomeric red fluorescent protein 1 (mRFP1) fusion gene [40] . We could observe the mRFP1 fluorescence in the dorsal part of the SON and in the magnocellular division of the PVN, and scattered mRFP1 fluorescence in the parvocellular division of the PVN. In comparing nontransgenic and transgenic rats under normal conditions, there were no differences between them in plasma osmolality, sodium, OXT, AVP, and the expression of the endogenous OXT gene and AVP gene in the SON and the PVN.
Colchicine has an anti-inflammatory effect, inhibiting neurotrophil motility and activity, and is one of the medications for the treatment of gout. Colchicine also blocks axonal transport, resulting in peptide accumulation in the cell body [4] . Many previous studies have used colchicine to allow the detection of very low levels of peptides in cell bodies (Table 1) .
In this review, we focus on 1) the expression of neuropeptides after icv administration of colchicine (Table 1) , 2) the effects of colchicine in AVP-eGFP transgenic rats, and 3) the effects of colchicine in OXT-mRFP1 transgenic rats, including recent research about the visualization of AVP and OXT in transgenic animals using a fluorescent protein, which is a new tool for studying the physiological role of AVP and OXT in the hypothalamo-neurohypophysial system (HNS).
Effects of colchicine on expression of neuropeptides in the SON and the PVN
It is well known that colchicine blocks axonal transport, resulting in peptide accumulation in the cell body [4] . Many previous studies have used colchicine to allow the detection of very low levels of peptides in cell bodies (Table 1) .
Adrenomedullin family
Adrenomedullin (AM) is a 52-amino-acid neuropeptide that was originally isolated from tissue extracts of human pheochromocytoma and was later found to be widely distributed in peripheral organs and the central nervous system (CNS) [42] . A similar 47-amino acid neuropeptide, adrenomedullin 2 (AM2)/intermedin, identical to intermedin, was first isolated from pufferfish [65, 72] and later from mammals [72, 95] from genomic databases [65, 72] . AM, AM2/intermedin, and amylin belongs to the calcitonin gene-related peptide (CGRP) superfamily. The effects of these two peptides are qualitatively and quantitatively similar [63, 74, 75, 81, 93, 97, 98] . We showed that central administration of AM activated OXT neurons [81, 101] and caused an elevation of plasma OXT levels in rats [81] . We also showed similar activation of OXT neurons and circulating OXT levels after central administration of AM2 [32, 33] . In immunohistochemistry for Fos, central administration of AM2 activated various areas in the forebrain, hypothalamus and brainstem in rats [32] .
AM and AM2 are found in various peripheral organs and the CNS [42, 46, 72, 94, 95, 98] . Immunohistochemical studies revealed that AM-like immunoreactivity (LI) was exhibited in the adrenal gland and hypothalamus, including SON, PVN, and infundibular nucleus in humans [76] and in rats [100] . In colchicine treated rats, AM-LI neurons were visualized more strongly in the SON and the PVN than those of control rats. The distribution of hypothalamic AM-LI neurons was similar in both colchicine treated and control rats. Abundant AM-LI fibers and varicosities were found in the hypothalamoneurohypophysial tract and the internal zone of the median eminence (ME) in the colchicine-treated rats, whereas in control rats few AM-LI fibers were observed.
AM2-LI was exhibited in the stomach and pituitary in mice [72] , the pituitary in rats [34, 46] and the heart, kidney and hypothalamus in humans [94] . AM2-LI neurons were co-localized with AVP-LI neurons in the PVN in humans [94] . In the rat brain, AM2-LI neurons were observed in the organum vasculosum of the lamina terminalis (OVLT), the median preoptic nucleus (MnPO), the SON, the PVN, the ventromedial hypothalamic nucleus (VMH), the arcuate hypothalamic nucleus (Arc), the locus coeruleus (LC), the area postrema (AP), the nucleus of the tractus solitarius (NTS), and the nucleus ambiguus (NA) [34] . AM2-LI neurons were widely distributed in the SON, and were found mainly in the magnocellular parts of the PVN. As well as AM, in the colchicine-treated rats, AM2-LI neurons were visualized more strongly than those in the vehicle rats in the SON, the magnocellular parts of the PVN and LC. In the OVLT, MnPO, VMH, Arc, AP, NTS and NA, AM2-LI neurons did not change significantly in comparison with the control. In the pituitary, AM2-LI terminals did not change significantly in comparison with the control. These results suggest that the axons of the AM-and AM2-LI neurons in the hypothalamus may terminate in the neurohypophysis.
Arginine vasopressin (AVP)
AVP is synthesized primarily in MNCs in the SON and the PVN, and released into the systemic circulation. AVP is also synthesized in the extra-hypothalamic area, including the LC [11, 21] . AVP is well known to play a role in water homeostasis and cardiovascular regulation, and also controls osmolality and blood pressure.
AVP-LI cells have been shown in the SON, PVN, and suprachiasmatic nucleus (SCN) in rats [6, 91] . AVP-LI cells were also demonstrated in the bed nucleus of the stria terminalis (BST), medial amygdala, dorsomedial hypothalamus (DMH), and LC in colchicine treated rats [10, 11, 88, 106] . In radioimmunoassay studies, immunoreactive (IR)-AVP levels are dramatically increased in the SON and the PVN, and marginally increased in the ME compared with controls after central administration of colchicine [49] . AVP is synthesized not only in the hypothalamus, but also in the extrahypothalamus. AVP may act as a neurotransmitter and/or neuromodulater in the CNS.
Corticotropin releasing hormone (CRH)
Corticotropin releasing hormone (CRH) is the main hypothalamic stimulatory hormone for adrenocorticotropic hormone (ACTH), which is secreted during stress [105] . CRH neurons are present in the parvocellular part of the PVN and project to the pituitary through the ME. CRH mRNA levels were increased in the PVN after central administration of colchicine [16] . CRH coexists with some neuropeptides, including AVP, OXT, neurotensin, and vasoactive intestinal polypeptide (VIP), in the PVN [15, 36, 77, 96] . Some previous studies showed that CRH neurons existed not only in the PVN, but also in the extra-hypothalamic area, such as cerebral cortex, hippocampus, central nucleus of the amygdala (CeA) and the BST in colchicine treated rats [18, 19, 58, 59, 63, 68, 78, 79, 85, 92] . As CRH is synthesized not only in the hypothalamus but also in the extra-hypothalamus, it may act as a neurotransmitter and/or neuromodulater in the CNS as well as AVP.
Oxytocin (OXT)
As well as AVP, OXT is synthesized primarily in MNCs in the SON and the PVN, and released into the systemic circulation from axon terminals in the neurohypophysis, particularly during parturition, lactation and in response to osmotic challenges [7] . The parvocellular OXT cells in the PVN project their axon terminals to the brainstem and the spinal cord, where OXT regulates autonomic functions [86] . Additional parvocellular OXT cells are found in the preoptic area and the lateral hypothalamus, whereas accessory magnocellular OXT cells are found scattered across the hypothalamus. OXT-LI fibers can be found throughout the brain, including the nucleus accumbens (NAcc), lateral septum, amygdala, and some areas in the hindbrain, brainstem, and spinal cord [14, 86] . A notable reduction of OXT-LI fibers was observed throughout the brain by the lesioning of the PVN [20] . Although little is known about the regulation of OXT release from these forebrain projections, they might contribute significantly to the regulation of behavior.
In a radioimmunoassay study, IR-OXT levels were increased in the SON and the PVN, and slightly increased in the ME compared with controls after central administration of colchicine in rats [49] . In colchicine-treated rats, OXT-LI cells were found clearly in the SON and the PVN [80] .
Effects of centrally administered colchicine in the AVP-eGFP transgenic rats
Transgenic expression is characterized by eGFP fluorescence in the SON, the PVN, the SCN and the PP [87, 102] . Physiological stimuli such as dehydration for 2 days, and chronic salt loading for 5 days, caused a marked increase in the intensity of eGFP fluorescence in the SON, the magnocellular division of the PVN and the internal layer of the ME, and upregulated the expression of the AVP-eGFP fusion gene in the SON and in the PVN but not in the SCN [25, 102] . Furthermore, stressful conditions such as bilateral adrenalectomy, endotoxin shock, and acute pain caused marked increases in the eGFP fluorescence in the parvocellular division of the PVN [82, 90] .
Recently, we reported the effects of colchicine on the expression of the AVP-eGFP fusion gene in the transgenic rats [99] . AVP-eGFP fluorescence was observed in the SON, the magnocellular division of the PVN, the SCN, the ME and the PP in the control and the colchicine-treated rats (Fig. 1) . In colchicine-treated rats, the intensity of the AVP-eGFP fluorescence was stronger in the SON (Fig. 1 A and B) , the magnocellular and the parvocellular divisions of the PVN (Fig. 1 C and D) , the SCN (Fig. 1 E and F) and in the internal layer of the ME (Fig. 1 G and H) compared to controls. However, in the colchicine-treated rats, the intensity of the AVP-eGFP fluorescence in the PP was similar to controls ( Fig. 1 O and P) . Interestingly, AVP-eGFP fluorescence was observed only in the LC of the rats after administration of colchicine (Fig. 1 J) . No fluorescence was observed in the LC of control rats (Fig. 1 I) . Other regions such as the NTS, the ventrolateral medulla (VLM) and the adrenal medulla did not exhibit AVP-eGFP fluorescence in either control or colchicine-treated rats (Fig. 1 K, L, M and N) .
We confirmed the effects of colchicine on eGFP-LI in the AVP-eGFP transgenic rats. eGFP-LI was observed in the SON, the magnocellular division of the PVN, the SCN and the ME in control and colchicine treated rats. In colchicinetreated rats, the intensity of the eGFP-LI was stronger in the SON, the magnocellular and parvocellular divisions of the PVN, the SCN and internal layer of the ME compared with controls. In contrast, in the LC, eGFP-LI was observed only in the colchicine treated rats but not in the control rats. No eGFP-LI was observed in any other regions (the NTS, the VLM and the adrenal medulla) of either colchicine or vehicle treated rats. We also showed that AVP-eGFP expression and tyrosine hydroxylase (TH)-LI were co-localized in the LC only in the colchicine-treated rats. Similarly, in situ hybridization histochemistry for eGFP mRNA revealed a significant increase in gene expression in the LC, the SON and the PVN after the treatment of colchicine. We have demonstrated the expression of the AVP gene and peptide, in the LC noradrenergic neurons, at least after colchicine treatment. We suggested that this transgenic rat represents a useful model to further study the physiological relevance of the vasopressinergic system originating from the LC in the CNS. 
Effects of centrally administered colchicine in the OXT-mRFP1 transgenic rats
Firstly, we generated rats bearing an OXT-enhanced cyan fluprescent protein (eCFP) fusion transgene designed from a murine construct previously shown to be specifically expressed in transgenic mice [39] . However, the expression of the transgene was unstable for unknown reasons. Secondly, we succeeded in generating transgenic rats bearing an OXT-mRFP1 fusion gene [40] . We could observe the mRFP1 fluorescence throughout the SON, especially in the dorsal parts. We could observe abundant mRFP1 fluorescence in the magnocellular division of the PVN and scattered mRFP1 fluorescence in the parvocellular division of the PVN. We also observed mRFP1 fluorescence in the internal layer of the ME and in the PP. In situ hybridization histochemistry showed mRFP1 mRNA localized in the SON and in the magnocellular and parvocellular divisions of the PVN. In comparing male and female transgenic rats under normal conditions, there were no differences in the expression of mRFP1 mRNA in the SON and the PVN. In comparing nontransgenic and transgenic rats under normal conditions, there were no differences in plasma osmolality, sodium, OXT, AVP, and the expression of the endogenous OXT gene and AVP gene in the SON and the PVN.
Previous studies have reported that OXT transcripts were significantly increased in the rat hypothalamus after chronic osmotic stimuli, such as salt loading (drinking 2% NaCl for 5 days) [45, 54, 109] . In our OXT-mRFP1 transgenic rats, the fluorescence of mRFP1 was marked increased by 5 to 7-fold throughout the SON and in the PVN, ME, and PP after salt loading for 5 days [40] . In situ hybridization histochemistry showed dramatically increased expression of the mRFP1 mRNA in the SON and the PVN after salt loading. Comparing nontransgenic and transgenic rats after salt loading, there were no differences in plasma osmolality, sodium, OXT, AVP, and the expression of the endogenous OXT gene and AVP gene in the SON and the PVN.
We examined the central effects of colchicine in the OXT-mRFP1 transgenic rats. In controls, the fluorescence of mRFP1 was observed in the SON and the magnocellular and parvocellular divisions of the PVN, the circularis nucleus (CN) and the PP (Fig. 2 and Fig. 3 ). Icv administration of colchicine caused a marked increase of fluorescence of mRFP1 in the SON, the PVN and CN, but not in the LC, and a decrease in the PP in comparison with control rats. No fluorescence of mRFP1 was observed in the ectopic area of either the controls or the colchicine-treated rats. The expected changes of fluorescence of mRFP1 in the SON, PVN, CN and the PP after icv administration of colchicine indicate that OXT-mRFP1 fusion protein may be transported by axonal flow and secreted from the PP into the systemic circulation, similarly to nontransgenic rats.
Conclusions
We did not observe any fluorescence of eGFP in the ectopic area of AVP, in the AVP-eGFP transgenic rats. We also did not observe any fluorescence of mRFP1 in the ectopic area of OXT in the OXT-mRFP1 transgenic rats. In colchicine-treated rats, we did not observe expression of both AVP-eGFP and OXT-mRFP1 in ectopic areas in these transgenic rats. The AVP neuron and OXT neuron have the same response to physiological stimulation both in the AVP-eGFP transgenic rat and in the OXT-mRFP1 transgenic rats, compared to non transgenic rats. Using these transgenic rats, we can identify the AVP and OXT neurons easily and see changes in the neuron's activity and will detect the release of AVP and OXT in realtime near future. Moreover, we can see smaller changes, because AVP-eGFP and OXT-mRFP1 transcription is more sensivive than endogenous AVP and OXT transcription to the same stimulation. Both the AVP-eGFP and the OXT-mRFP1 transgenic rats are useful animal models to study dynamic changes in AVP and OXT in the HNS.
